Supernus Pharmaceuticals SUPN Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's other income, net (note 6)?
- Supernus Pharmaceuticals (SUPN) reported other income, net (note 6) of $2.38M in Q1 2026.
- How has Supernus Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Supernus Pharmaceuticals's other income, net (note 6) decreased by 46.2% year-over-year, from $4.43M to $2.38M.
- What is the long-term trend for Supernus Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's other income, net (note 6) has grown at a 0.8% compound annual growth rate (CAGR), from -$12.85M to $13.25M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.